AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00966901
Drug: No Patch Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As a negative control, a marked site on the lower back or buttock was assigned as test area, but no patch was applied.
Trial: NCT00813436
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline liquid, intranasally administered
Trial: NCT01578499
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate tablets.
Trial: NCT02468713
Drug: Combiflex® lipid peri
FDA approved: no
EMA approved: no
PMDA approved: no
Description: total parenteral nutrition solutions containing glucose, amino acids, electrolyte, soybean oil
Trial: NCT02468713
Drug: Winuf® peri
FDA approved: no
EMA approved: no
PMDA approved: no
Description: total parenteral nutrition solution containing glucose, amino acids, electrolyte, soybean oil, medium chain triglyceride, olive oil and fish oil
Trial: NCT00508157
Drug: Continued Antipsychotic (Risperidone or Quetiapine or Olanzapine)
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, According to summary of product characteristics (SmPC)
Trial: NCT00614757
Drug: N-acetylcysteine 20% 4ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine 20% 4ml
Trial: NCT00614757
Drug: N-acetylcysteine 20% in 4 ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine 20% in 4 ml
Trial: NCT00073008
Drug: GW572016 (lapatinib)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tyrosine kinase inhibitor
Trial: NCT02350088
Drug: probiotics
RxNorm normalized name: probiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: probiotics
Trial: NCT02350088
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02130700
Drug: VT-464: given orally twice daily in 28-day cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral VT-464 given twice daily, in continuous 28-day cycles at the recommended Phase 2 dose
Trial: NCT03828682
Drug: Mycophenolic Acid Oral Product
RxNorm normalized name: mycophenolic acid Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mycophenolic acid tablets
Trial: NCT03831269
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will be randomly distributed and start taking azithromycin according to the known dose /kg/day for repeated cycles till improvement or reaching the end of study
Trial: NCT00808470
Drug: beta-carotene, vitamins C and E, magnesium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mint-flavored tablets per day, taken once daily~total daily dose label claim: micronutrient combination of 500 mg vitamin C (magnesium ascorbate), 315 mg magnesium (magnesium citrate, magnesium ascorbate, magnesium stearate), 267 mg vitamin E (d-α-tocopherol acetate), and 18 mg beta carotene.
Trial: NCT02356107
Drug: 5-hydroxytryptophan and Creatine monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00555776
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo is given with the same definition as Gabapentin
Trial: NCT02760121
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00320697
Drug: Placebo pill + placebo patch
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.
Trial: NCT01583283
Drug: ACY-1215
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation up to 480 mg administered orally on Days 1-5, 8-12 and 15-19 of a 28 day dosing schedule.
Trial: NCT02669667
Drug: MEDI9314
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of MEDI9314
Trial: NCT02669667
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of placebo
Trial: NCT04399538
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT00840034
Drug: LY2216684
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose is 6 milligrams (mg), then titrate up to 9 mg, 12 mg, or 18 mg (3 tablets) administered orally (PO), once daily (QD) for up to 10 weeks followed by a 2 week taper.
Trial: NCT00840034
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 tablets PO QD for up to 12 weeks
Trial: NCT04671056
Drug: MGL-3196
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MGL-3196 100 mg tablet administered orally in the morning for 13 days
Trial: NCT01777737
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical capsules to cotrimoxazole
Trial: NCT01941537
Drug: ILV-094
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of ILV-094
Trial: NCT01941537
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twenty patients will be enrolled in the ILV-094 placebo arm. A loading IV dose of a placebo will be given at baseline (Day 0), followed by five additional IV doses of placebo every two weeks (Weeks 2, 4, 6, 8, and 10).
Trial: NCT04798326
Drug: Xgeva®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects would receive a single 120mg (1.7 mL) of Xgeva® through subcutaneous injection, on the first day of treatment.
Trial: NCT04091945
Drug: LT3001 Drug Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active comparator
Trial: NCT04091945
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT02552953
Drug: CYC065
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02419651
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Women will receive 100 mg diclofenac 1 hour before the procedure
Trial: NCT02419651
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women will receive a placebo 1 hour before the procedure
Trial: NCT01482299
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAD001 (everolimus) 10 mg daily, orally without interruption.~1 cycle is equal to 4-week treatment. Treatment will be continued unless disease progression or intolerability.
Trial: NCT02474355
Drug: AZD9291 Dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients to be provided with AZD9291 every 6 weeks (+/- 7 days)
Trial: NCT00298363
Drug: ETV placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match ETV QD
Trial: NCT00846690
Drug: benzocaine
RxNorm normalized name: Benzocaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20% benzocaine., topical placement onto site, minimal amount, for 1 minute
Trial: NCT01198535
Drug: Gamma-Secretase Inhibitor RO4929097
RxNorm normalized name: .GAMMA.-OCTALACTONE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02263729
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01928199
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00315718
Drug: Extract from Hintonia latiflora bark
RxNorm normalized name: quebracho bark extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00755261
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The Day 1 6- hour continuous IV infusion must be done through a central venous catheter.
Trial: NCT05672680
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo equivalent
Trial: NCT03959488
Drug: MEDI8897
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-RSV monoclonal antibody with an extended half-life
Trial: NCT01026818
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by mouth, daily or on demand for 9 months
Trial: NCT00571116
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01982799
Drug: oral naproxen
RxNorm normalized name: naproxen Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxen
Trial: NCT00575471
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets once daily for 12 weeks
Trial: NCT02932605
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04575584
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
Trial: NCT02085070
Drug: MK-3475
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV MK-3475
Trial: NCT04511000
Drug: Lipilou®(generic atorvastatin drug) 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients assigned to experimental group are treated with Lipilou® 20 mg
Trial: NCT04511000
Drug: Lipilou®(generic atorvastatin drug) 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients assigned to comparator group are treated with Lipilou® 10 mg
Trial: NCT02653898
Drug: DHA-PIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered monthly (weight-based) on days 1-3, during months 1, 2, and 3 in the MMP arm and also as a first line agent for P.v malaria recurrence in both MMP and FSAT treatment arms
Trial: NCT00004197
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004197
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04293172
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the open-label Run-in period (patients aged 6 to \<24 months only) will receive ticagrelor 5 mg twice a day (body weight 6 to ≤9 kg), 10 mg twice a day (body weight \>9 to ≤12 kg) or 15 mg twice a day (body weight \>12 to ≤24 kg) for 14 days.~The double-blind IP will be based on 5 weight bands:~* 6 to ≤9 kg: ticagrelor 5 mg or matching placebo, twice a day~* \>9 to ≤12 kg: ticagrelor 10 mg or matching placebo, twice a day~* \>12 to ≤24 kg: ticagrelor 15 mg or matching placebo, twice a day~* \>24 to ≤48 kg: ticagrelor 30 mg or matching placebo, twice a day~* \>48 kg: ticagrelor 45 mg or matching placebo, twice a day
Trial: NCT00715520
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive one oral tablet of placebo 2 hours prior to measuring wrist extension movements.~The order in which Placebo is given will be randomized per participant.
Trial: NCT01378715
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients with coronary artery disease referred for coronary angiography and subsequently PCI will be enrolled and randomized to pre-treatment with rosuvastatin (20mg 12 hours prior + 20mg immediately prior PCI).
Trial: NCT02072070
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control(Normal Saline)
Trial: NCT01962246
Drug: Oxaliplatin; Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for eight cycles postoperation
Trial: NCT00496587
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 mg/m\^2 By Mouth Twice Daily On Days 1-21.
Trial: NCT01937884
Drug: Parenteral Nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00004088
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03564132
Drug: Yigansan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yigansan granules
Trial: NCT03564132
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-tenth concentration of Yigansan manufactured to mimic Yigansan granules
Trial: NCT02806830
Drug: Optive
RxNorm normalized name: optive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optive eye drops will be prescribed to each included patients after their second intravitreal injection; patients will received 1 drop in the affected eye 2 times a day during 3 days
Trial: NCT03706469
Drug: TAK-831 T2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-831 T2 Tablets.
Trial: NCT00332774
Drug: Nepafenac ophthalmic solution 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop 4 times daily for 90 days
Trial: NCT00332774
Drug: Ketorolac Tromethamine ophthalmic solution 0.4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop 4 times daily for 90 days
Trial: NCT00510484
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02838472
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid administration at a doses of 75-80% of the upper limit of allowance according to IOM
Trial: NCT00351936
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02081001
Drug: Novo Nordisk GlucaGen®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
Trial: NCT02081001
Drug: G-Pump™ (glucagon infusion)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
Trial: NCT01343966
Drug: MABT5102A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeating subcutaneous injection
Trial: NCT01343966
Drug: MABT5102A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeating intravenous infusion
Trial: NCT01343966
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeating subcutaneous injection
Trial: NCT01343966
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeating intravenous infusion
Trial: NCT03299725
Drug: colloidal bismuth sub-citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: colloidal bismuth sub-citrate administered as an adjunctive therapy in combination with esomeprazole, amoxicillin and metronidazole
Trial: NCT04290325
Drug: HMPL-453
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMPL-453 tablet
Trial: NCT03013790
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive Melatonin at 2 different doses or a placebo
Trial: NCT04165135
Drug: Standard of Care for Haemophilia A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There is no pre-determined studied medicinal product. Any treatment (including treatments started during the observational period) will be administered according to standard clinical practice, independently of participation in the current study, according to clinician's independent therapeutic decision.
Trial: NCT02703896
Drug: Drug either PPIS or H2RA and prokinetics
RxNorm normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug intervention ( dose unit mg) Two oral doses 8:00 p.m. and 6:00 a.m. (n=60) total 10 groups~1. Group C (placebo),Group L (lansoprazole15 ), Group LD (Lansoprazole 15 +domperidone 10 )~2. Group C ,R (rabeprazole 10), RM (rabeprazole 10 + metoclopramide 10)~3. Group C , E (esomeprazole 20 ), and EM (esomeprazole 20 + metoclopramide 10)~4. Group C, P (pantoprazole 20), and PD (pantoprazole 20 + domperidone 10 mg)~5. Group C, O (omeprazole 20), OD (omeprazole 20 + domepridone 10), OM (omeprazole 20 + metoclopramide 10)~6. Group C,T (cimetidine 200), TD (cimetidine 200 + domperidone 10)~7. Group C , Z (ranitidine 150), ZD (ranitidine 150 + domperidone 10)~8. Group C , N (nizatidine 150),NM (nizatidine 150 + metoclopramide 10)~9. Group C, F (famotidine 20 mg), and FM (famotidine 20 mg + metoclopramide 10)~10. Group C,S (lafutidine 10), SD (lafutidine 10 + domperidone 10), and Group SM (lafutidine 10 + metoclopramide 10)
Trial: NCT03132974
Drug: Sogyeonghwalhyeol-tang granule
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sogyeonghwalhyeol-tang herbal extract granule
Trial: NCT01111682
Drug: Hypertonic Saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% hypertonic saline continuous infusion, with intermittent boluses as needed
Trial: NCT00778726
Drug: Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01420042
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lemon flavoured cordial and Water for Injection
Trial: NCT03062397
Drug: JPI-289 High-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JPI-289 High dose will be intravenously administered during 24 hours
Trial: NCT03062397
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same dosage of JPI-289 Low and Hogh dose will be intravenously administered during 24 hours
Trial: NCT02079298
Drug: 2. Treatment with both fluconazole and Ibuprofen.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02756598
Drug: Sufentanil I
RxNorm normalized name: sufentanil Injection
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bolus dose of sufentanil 1 microgram/kg
Trial: NCT02756598
Drug: Sufentanil II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bolus dose of sufentanil 0.5 microgram/kg
Trial: NCT02362152
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical field treatment as prescribed by dermatologist
Trial: NCT02147392
Drug: [11C]ER-176
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02463006
Drug: Porous variant of Bioactive Glass.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flap surgery with Porous variant of Bioactive Glass.
Trial: NCT02463006
Drug: Non porous variant of Bioactive Glass.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flap surgery with non-Porous variant of Bioactive Glass.
Trial: NCT00240656
Drug: spironolactone captopril carvedilol
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03142256
Drug: Truvada 200Mg-300Mg Tablet
RxNorm normalized name: Truvada 200mg-300mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both study arms will be offered Truvada as PrEP. Only one arm will be randomized to the conditional cash transfer.
Trial: NCT01826045
Drug: Poly-gamma Glutamic Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01826045
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01084213
Drug: Intermittent screening and treatment of malaria in pregnancy (IST)
RxNorm normalized name: Plasmodium malariae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheduled intermittent screening of study women using rapid diagnostic test and treatment of those who are RDT positive during ante-natal clinic visits in the 2nd and 3rd trimester with arthemether lumefantrine.
Trial: NCT01084213
Drug: SP-IPTp
RxNorm normalized name: SPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study women will receive at least two doses of Sulfadoxine Pyrimethamine during their pregnancy, one at each of the recommended ante-natal visits during the 2nd and 3rd trimester.
Trial: NCT02779270
Drug: BAY987518
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply the assigned test product to all sun-exposed areas of the face and body while avoiding contact with mouth, eyes and eyelids.~Formulation: V27-104
Trial: NCT04697654
Drug: TLC19 Vehicle
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposome Inhalation Suspension (same formulation as TLC19 but without the active ingredient, HCQ)
Trial: NCT04108208
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered orally.
Trial: NCT04108208
Drug: Androgen-deprivation Therapy (ADT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will continue to receive ADT with gonadotrophin-releasing hormone agonists (GnRHa) who have not been surgically castrated.
Trial: NCT04026711
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily for 12 weeks
Trial: NCT00636961
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo devices and hard gelatin capsules
Trial: NCT01588405
Drug: UT-15C SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will transition in the hospital from Remodulin to UT-15C SR within 5 days of the start of the transition. The dose of Remodulin will be decreased as the dose of UT-15C SR is increased over the 5 days. Once subjects have been transitioned from Remodulin, the dose of UT-15C SR will continue to be modified / titrated to the appropriate optimal dose for that subject throughout the rest of the study.
Trial: NCT01216332
Drug: High-dose trivalent inactivated influenza vaccine
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL of high-dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine.
Trial: NCT01216332
Drug: Standard dose trivalent inactivated influenza vaccine
RxNorm normalized name: diphtheria toxoid vaccine, inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL standard dose trivalent inactivated influenza vaccine